Sanofi-Aventis appoints senior managers in emerging markets

Sanofi-Aventis has appointed a number of senior managers in emerging markets. Patrick Aghanian who is currently head of the company's operations in Russia is becoming head of the Eurasia region. Apart from Russia, he will take responsibility for business in Ukraine, Belarus and central Asia (centred in Kazakhstan). He has previously worked in the region for a number of companies, including GlaxoSmithKline, Novartis and Sandoz. Thomas Kelly who is currently head of greater China has been promoted to head Asia Region covering also Thailand, Singapore, Malaysia, Indonesia, Vietnam and the Philippines. Mr Kelly's previous jobs included marketing positions in Johnson&Johnson, Novo Nordisk and Schering-Plough. Heraldo Marchezini, head of Sanofi-Aventis's business in Brazil, has been promoted to head of the Latin America region, and the responsibilities of Jeremy Moulding, head the Japan & Pacific Region, have been expanded to cover South Korea.

Sanofi-Aventis has appointed a number of senior managers in emerging markets. Patrick Aghanian who is currently head of the company's operations in Russia is becoming head of the Eurasia region. Apart from Russia, he will take responsibility for business in Ukraine, Belarus and central Asia (centred in Kazakhstan). He has previously worked in the region for a number of companies, including GlaxoSmithKline, Novartis and Sandoz. Thomas Kelly who is currently head of greater China has been promoted to head Asia Region covering also Thailand, Singapore, Malaysia, Indonesia, Vietnam and the Philippines. Mr Kelly's previous jobs included marketing positions in Johnson&Johnson, Novo Nordisk and Schering-Plough. Heraldo Marchezini, head of Sanofi-Aventis's business in Brazil, has been promoted to head of the Latin America region, and the responsibilities of Jeremy Moulding, head the Japan & Pacific Region, have been expanded to cover South Korea.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?